Gastrointestinal Cancer News

ORLANDO, Fla. — A study presented at the AAP National Conference & Exhibition revealed that among young adult and adolescent cancer survivors, provider recommendation was the strongest predictor of intent to receive HPV vaccine, which, in turn, was strongly predictive of subsequent initiation of the vaccine series.

The University of Chicago Medicine has been awarded $6 million over 5 years to test novel ways to improve colorectal cancer screening and follow-up among individuals who have not previously been screened, according to a press release.

MUNICH — Neoadjuvant treatment with nivolumab and ipilimumab induced major pathologic response in 100% of patients with early-stage, mismatch repair-deficient colon cancers, according to results of the phase 2 NICHE trial presented at European Society for Medical Oncology Congress.

MUNICH — The combination of nivolumab and low-dose ipilimumab may become a new first-line treatment option for patients with microsatellite instability-high metastatic colorectal cancer, according to results from the phase 2 CheckMate-142 trial presented at European Society for Medical Oncology Congress.

PHILADELPHIA — An artificial intelligence program helped achieve real-time pathology of diminutive polyps during colonoscopy screening, according to research presented at the American College of Gastroenterology Annual Scientific Meeting.

Rates of colorectal cancer among young adults in Europe have increased by 6% every year for the last 10 years, according to research presented at UEG Week 2018 in Vienna.

Liver cancer incidence and related mortality rates have been increasing significantly in the United States over the last 15 years, following increasing trends in obesity, nonalcoholic fatty liver disease and alcohol use.

The FDA granted priority review to a supplemental new drug application that seeks approval of trifluridine and tipiracil for previously treated advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, according to the agent’s manufacturer.

Treatment with a novel, synthetic, long-peptide HPV-16 vaccine plus nivolumab yielded promising response rates and survival outcomes among a small cohort of patients with incurable HPV-16-positive cancer, according to results from a single-arm phase 2 study.

The FDA approved levoleucovorin, a folate analog, for injection for three indications.